Ascletis selected ASC30_39 FDC, combining oral GLP-1R agonist ASC30 and amylin receptor agonist ASC39, for obesity treatment. The company plans to submit IND to FDA in Q3 2026.
Ascletis announces ASC30_39 FDC, combining oral GLP-1R and amylin receptor agonists for obesity treatment, with FDA IND submission expected Q3 2026. Preclinical studies show excellent bioavailability and tolerability.
Akeso presented Phase Ib/II study results at ELCC 2026 showing cadonilimab combination therapy achieved 7.0 months median PFS and 95.2% DCR in immunotherapy-resistant advanced NSCLC patients with manageable safety profile.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.